ATL has released a new versionof its power mode color Doppler technology for imaging blood flowin small vessels. ATL increased the performance of the technologyand renamed it Color Power Angio Imaging, the Bothell, WA, companysaid last month. Color
ATL has released a new versionof its power mode color Doppler technology for imaging blood flowin small vessels. ATL increased the performance of the technologyand renamed it Color Power Angio Imaging, the Bothell, WA, companysaid last month.
Color Power Angio Imaging supersedes Doppler Power Imagingas the marketing term for the company's power mode Doppler technology.The technique displays the amplitude of blood flow rather thanthe velocity, giving physicians a better look at weak blood flowin small vessels.
Most major ultrasound vendors have adopted different versionsof Doppler blood-vessel roadmapping and the technology has beenwell received by clinicians. Few clinical papers on the technologyhave been published, due to its novelty, however. That could changewith this year's Radiological Society of North America meeting,according to ATL president David Perozek.
"At the RSNA conference there will be a number of clinicalpapers presented, indicating and evaluating the clinical utilityof the Color Power Angio mode," Perozek said.
Also last month, ATL released a new intraoperative scanheadfor vascular surgery applications. The Entos CL10-5 transducercan help vascular surgeons identify anatomic defects that mayresult from surgery, enabling them to take corrective action whilestill in the operating room, according to the company.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.